David Schaffer, Ph.D., is listed as an executive officer and director on 1 SEC Form D filing by 1 issuer in Sep 2018: 4D Molecular Therapeutics Inc (Emeryville, CA — biotechnology — 2018; $90M reported sold to 31 investors).
What this means One deal on file with the SEC, filed Sep 2018. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Charles Theuer, Ph.D. (1 shared filing), David Kirn, M.D. (1 shared filing), Hoyoung Huh, M.D., Ph.D. (1 shared filing), Leisa Johnson, Ph.D. (1 shared filing), Margi McLaughlin (1 shared filing) and 3 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around David. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 1 public filing for David Schaffer, Ph.D., and found 1 difference: Bankruptcy case: Ethan O. Janke and Theresa N. Janke.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.